|CONFERENCE DAY 2 – FRIDAY, 15 March|
|08:00–17:00||Registration, Poster Presentations and Exhibition open|
|08:45–08:50||Opening Remarks |
by conference organizer BIOCOM AG
|08:50–10:30||Plenary Session |
Update and progress report with regard to AMR innovations for human and animal health
|11:00–12:30||Parallel Sessions |
Market Access - US market as role model or does Europe need a specific/own way?
The session will discuss one of the major topics in the AMR community: the broken economic model. It will focus on current instruments available to incentivise AMR innovation and looks at new PUSH and PULL strategies proposed by experts. A panel will shed light on the SMEs perspective: what are their needs with regard to reimbursement and return of investment and which instrument would fit the best to support growing the community?
• Elmar Nimmesgern, Global AMR R&D Hub (Chair & Moderation)
• Marie Petit, BEAM Alliance & Villiger Valuation, FR
• Colm Leonhard, National Institute for Health and Clinical Excellence, UK
• Enrico Baraldi, Uppsala University, SE
• Achim Plum, Curetis N.V., DE
|Session 5 |
Surveillance – A new tool to improve R&D for drugs and diagnostics, the challenge of data integration and the role of large industry/SMEs
The session will have a special focus on how surveillance data can be used to create a more efficient, reliable and successful drug and diagnostic development process to combat antibiotic resistance in the long-term. It will present current strategies and international efforts of sharing and collecting existing data and will discuss the role of industry and SMEs within this challenge. Another aspect will cover the challenges to integrate human and animal health data and the related challenge to identify relevant diagnostic tools.
• Ghada Zoubiane, Wellcome Trust, UK
• Didem Torumkuney, GlaxoSmithKline, UK
• Adam Zerda, BD, US (requested)
|12:30–14:00||Lunch, Exhibition and Poster Presentations|
|14:00–15:30||Parallel Sessions and Investor Partnering |
|Session 6 |
This session will focus on innovative SMEs with more traditional human therapies like small molecules or peptides to directly target resistant bacteria. The session will be jointly moderated by BEAM Alliance and CARB-X.
• Rich Lawson, CARB-X, US
• Marc Gitzinger, BioVersys AG, CH
• Marc Lemonnier, Antabio SAS, FR
• Els Beirnaert, CEO, Aelin Therapeutics, BE
• Albert Palomer, ABAC Therapeutics, ES (requested)
|Session 8 |
To address the one health approach in tackling spreading antimicrobial resistance and the growing need for alternatives to antibiotics, track 8 will present therapeutic and diagnostic innovations in animal health showcasing new antimicrobial approaches and innovative AMR diagnostics for usage in veterinary settings. The session particularly aims at providing insights into possible synergies between human and animal health experts to fight AMR.
• Dagmar Köhler-Repp, Ripac Labor GmbH, DE
• Sven Arnouts, PROVAXS - Ghent University, BE
• n.n., Friedrich Loeffler Institute, DE
• Martin Griessl, Lisando GmbH, DE
• Zoetis (requested)
|Investor Partnering |
Pre-scheduled 1-to-1 meetings (13:30–15:30)
|16:00–17:30||Plenary Session |
|17:30–18:30||Closing Reception and Poster Prize Ceremony|